Mufg Securities Americas Inc. Takes $2.94 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Mufg Securities Americas Inc. acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 5,647 shares of the medical research company’s stock, valued at approximately $2,938,000.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Barrett & Company Inc. purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $28,000. FPC Investment Advisory Inc. acquired a new position in Thermo Fisher Scientific during the fourth quarter worth $28,000. Pillar Financial Advisors LLC purchased a new position in Thermo Fisher Scientific in the fourth quarter worth $29,000. Missouri Trust & Investment Co acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at $29,000. Finally, Endeavor Private Wealth Inc. acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $30,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

TMO has been the subject of several recent analyst reports. UBS Group reduced their price objective on shares of Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating for the company in a research note on Thursday, April 24th. Morgan Stanley boosted their price target on Thermo Fisher Scientific from $647.00 to $678.00 and gave the stock an “overweight” rating in a research note on Friday, January 31st. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the company a “buy” rating in a research note on Wednesday, April 23rd. Evercore ISI decreased their target price on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a research report on Thursday, April 24th. Finally, Argus cut their price target on Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating for the company in a research note on Tuesday, April 29th. Five research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $607.43.

Insider Activity at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total value of $5,166,700.00. Following the completion of the transaction, the chief executive officer now owns 115,174 shares of the company’s stock, valued at approximately $59,506,950.58. This represents a 7.99% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Michael A. Boxer sold 3,775 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the sale, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. This represents a 25.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 14,075 shares of company stock worth $7,305,942. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Stock Performance

Shares of TMO stock opened at $428.88 on Wednesday. Thermo Fisher Scientific Inc. has a one year low of $401.75 and a one year high of $627.88. The company has a 50 day moving average price of $460.85 and a 200 day moving average price of $513.11. The firm has a market capitalization of $161.90 billion, a price-to-earnings ratio of 25.95, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The company had revenue of $10.36 billion during the quarter, compared to analyst estimates of $10.23 billion. During the same period in the prior year, the firm posted $5.11 earnings per share. The firm’s revenue was up .2% on a year-over-year basis. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were given a $0.43 dividend. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date was Friday, March 14th. This represents a $1.72 annualized dividend and a dividend yield of 0.40%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.09%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.